As such, there is an urgent clinical need to identify new therapeutic strategies to improve existing treatments to target HRD and exploit other DNA repair vulnerabilities that exist in cancer, including deficiencies in non-homologous end joining, mismatch repair, base excision repair (BER), and ATM signaling (Gourley et al., 2019). The gene discussed is ATM; the disease is cancer.